Literature DB >> 17449239

Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.

Andy J Cheng1, Ngan Ching Cheng, Jette Ford, Janice Smith, Jayne E Murray, Claudia Flemming, Maria Lastowska, Michael S Jackson, Christopher S Hackett, William A Weiss, Glenn M Marshall, Ursula R Kees, Murray D Norris, Michelle Haber.   

Abstract

Overexpression of the human MYCN oncogene driven by a tyrosine hydroxylase promoter causes tumours in transgenic mice that recapitulate the childhood cancer neuroblastoma. To establish an in vitro model to study this process, a series of isogenic cell lines were developed from these MYCN-driven murine tumours. Lines were established from tumours arising in homozygous and hemizygous MYCN transgenic mice. Hemizygous tumours gave rise to cell lines growing only in suspension. Homozygous tumours gave rise to similar suspension lines as well as morphologically distinct substrate-adherent lines characteristic of human S-type neuroblastoma cells. FISH analysis demonstrated selective MYCN transgene amplification in cell lines derived from hemizygous mice. Comparative genomic hybridisation (CGH) and fluorescence in situ hybridisation (FISH) analysis confirmed a range of neuroblastoma-associated genetic changes in the various lines, in particular, gain of regions syntenic with human 17q. These isogenic lines together with the transgenic mice thus represent valuable models for investigating the biological characteristics of aggressive neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449239      PMCID: PMC3000537          DOI: 10.1016/j.ejca.2007.03.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  23 in total

1.  Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma.

Authors:  W A Weiss; T Godfrey; C Francisco; J M Bishop
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

2.  Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.

Authors:  N Bown; S Cotterill; M Lastowska; S O'Neill; A D Pearson; D Plantaz; M Meddeb; G Danglot; C Brinkschmidt; H Christiansen; G Laureys; F Speleman; J Nicholson; A Bernheim; D R Betts; J Vandesompele; N Van Roy
Journal:  N Engl J Med       Date:  1999-06-24       Impact factor: 91.245

Review 3.  Neuroblastoma: biological insights into a clinical enigma.

Authors:  Garrett M Brodeur
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

4.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

Authors:  R C Seeger; G M Brodeur; H Sather; A Dalton; S E Siegel; K Y Wong; D Hammond
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

5.  Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.

Authors:  Maria Łastowska; Yeun-Jun Chung; Ngan Cheng Ching; Michelle Haber; Murray D Norris; Ursula R Kees; Andrew D J Pearson; Michael S Jackson
Journal:  Genes Chromosomes Cancer       Date:  2004-06       Impact factor: 5.006

6.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

7.  MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.

Authors:  Chitra F Manohar; James A Bray; Helen R Salwen; Janice Madafiglio; Andy Cheng; Claudia Flemming; Glenn M Marshall; Murray D Norris; Michelle Haber; Susan L Cohn
Journal:  Oncogene       Date:  2004-01-22       Impact factor: 9.867

8.  Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.

Authors:  Christopher S Hackett; J Graeme Hodgson; Mark E Law; Jane Fridlyand; Kazutoyo Osoegawa; Pieter J de Jong; Norma J Nowak; Daniel Pinkel; Donna G Albertson; Ajay Jain; Robert Jenkins; Joe W Gray; William A Weiss
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 9.  A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors.

Authors:  Robert A Ross; June L Biedler; Barbara A Spengler
Journal:  Cancer Lett       Date:  2003-07-18       Impact factor: 8.679

10.  Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.

Authors:  Catherine A Burkhart; Andy J Cheng; Janice Madafiglio; Maria Kavallaris; Mario Mili; Glenn M Marshall; William A Weiss; Levon M Khachigian; Murray D Norris; Michelle Haber
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506

View more
  18 in total

Review 1.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

2.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Authors:  Jan J Molenaar; Raquel Domingo-Fernández; Marli E Ebus; Sven Lindner; Jan Koster; Ksenija Drabek; Pieter Mestdagh; Peter van Sluis; Linda J Valentijn; Johan van Nes; Marloes Broekmans; Franciska Haneveld; Richard Volckmann; Isabella Bray; Lukas Heukamp; Annika Sprüssel; Theresa Thor; Kristina Kieckbusch; Ludger Klein-Hitpass; Matthias Fischer; Jo Vandesompele; Alexander Schramm; Max M van Noesel; Luigi Varesio; Frank Speleman; Angelika Eggert; Raymond L Stallings; Huib N Caron; Rogier Versteeg; Johannes H Schulte
Journal:  Nat Genet       Date:  2012-10-07       Impact factor: 38.330

3.  Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Authors:  Zaowen Chen; Yunfu Lin; Eveline Barbieri; Sue Burlingame; John Hicks; Andrew Ludwig; Jason M Shohet
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

Review 4.  Targeting ALK in neuroblastoma--preclinical and clinical advancements.

Authors:  Erica L Carpenter; Yael P Mossé
Journal:  Nat Rev Clin Oncol       Date:  2012-05-15       Impact factor: 66.675

5.  High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.

Authors:  Jimmy K Stauffer; Rimas J Orentas; Erin Lincoln; Tahira Khan; Rosalba Salcedo; Julie A Hixon; Timothy C Back; Jun S Wei; Rajesh Patidar; Young Song; Laura Hurd; Maria Tsokos; Edwin W Lai; Graeme Eisenhofer; William Weiss; Javed Khan; Jon M Wigginton
Journal:  Cancer Invest       Date:  2012-06       Impact factor: 2.176

6.  Myc proteins as therapeutic targets.

Authors:  W C Gustafson; W A Weiss
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

7.  Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.

Authors:  Lin Xiao; Klaartje Somers; Murray D Norris; Michelle Haber; Jayne Murray; Ruby Pandher; Mawar Karsa; Emma Ronca; Angelika Bongers; Rachael Terry; Anahid Ehteda; Laura D Gamble; Natalia Issaeva; Katerina I Leonova; Aisling O'Connor; Chelsea Mayoh; Pooja Venkat; Hazel Quek; Jennifer Brand; Frances K Kusuma; Jessica A Pettitt; Erin Mosmann; Adam Kearns; Georgina Eden; Stephanie Alfred; Sophie Allan; Lei Zhai; Alvin Kamili; Andrew J Gifford; Daniel R Carter; Michelle J Henderson; Jamie I Fletcher; Glenn Marshall; Ricky W Johnstone; Anthony J Cesare; David S Ziegler; Andrei V Gudkov; Katerina V Gurova
Journal:  Clin Cancer Res       Date:  2021-05-16       Impact factor: 12.531

Review 8.  Cancer gene discovery in mouse and man.

Authors:  Jenny Mattison; Louise van der Weyden; Tim Hubbard; David J Adams
Journal:  Biochim Biophys Acta       Date:  2009-03-12

9.  A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse.

Authors:  Seiki Haraguchi; Akira Nakagawara
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

10.  NBAT1/CASC15-003/USP36 control MYCN expression and its downstream pathway genes in neuroblastoma.

Authors:  Prasanna Kumar Juvvuna; Tanmoy Mondal; Mirco Di Marco; Subazini Thankaswamy Kosalai; Meena Kanduri; Chandrasekhar Kanduri
Journal:  Neurooncol Adv       Date:  2021-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.